Cochrane Abstracts
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431206/0/Long.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/0/Long. Accessed May 1, 2025.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/0/Long
Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 May 01]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/0/Long.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
ID - 431206
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/0/Long
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
